Downward price movements and volatility in Nkarta's stock are frequently driven by broader macroeconomic headwinds and cautious investor sentiment toward pre-revenue, clinical-stage biotechnology companies. Because early-stage biopharmaceutical firms rely heavily on long-term clinical trials rather than immediate commercial product revenue, their valuations remain highly sensitive to risk-off market rotations, interest rate shifts, and cash burn concerns. In the absence of major near-term clinical catalysts, small-cap biotech equities often experience sentiment-driven selling pressure.